Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma.
We report the activity and toxicity of docetaxel in 12 evaluable heavily pretreated patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. In all, 42% achieved a partial response, 25% achieved stable disease. Median duration of response was 16 (10-21) weeks. The median overall survival was 70 (9-178) weeks and for responders it was 120 (22-178) weeks. One patient developed one episode of neutropenic sepsis. Docetaxel has limited activity in this group of patients.
Zekri
J M
JM
Cancer Research Centre, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK. jmzekri@hotmail.com
Hough
R E
RE
Davies
J M
JM
Molife
R
R
Hancock
B W
BW
Lorigan
P C
PC
D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D001772:Blood Cell Count; D018572:Disease-Free Survival; D000077143:Docetaxel; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011379:Prognosis; D015996:Survival Rate; D043823:Taxoids; D013997:Time Factors; D016896:Treatment Outcome
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel